Wednesday, January 13, 2021 8:25:13 PM
I feel that Bunka was alluding to this fact many times when he expressed his reasons for uplisting. He often hinted at the difficulty of raising money while not being on a senior exchange.
Also, as the company was increasingly needing to raise more and more money to support the greater numbers of studies, patent costs, legal fees and general costs, it only makes sense that to grow the company at all they would need to uplist or risk barely scraping by or going broke, doing a few studies a year.
I believe Chris saw this as a way to get the ball rolling in a bigger way and hopefully garnering more attention at the same time. The more studies they do concurrently, the faster they'll find real partners. The old "Go big or go home" routine seems to be the plan.
Also, as the company was increasingly needing to raise more and more money to support the greater numbers of studies, patent costs, legal fees and general costs, it only makes sense that to grow the company at all they would need to uplist or risk barely scraping by or going broke, doing a few studies a year.
I believe Chris saw this as a way to get the ball rolling in a bigger way and hopefully garnering more attention at the same time. The more studies they do concurrently, the faster they'll find real partners. The old "Go big or go home" routine seems to be the plan.
Recent LEXX News
- Lexaria Bioscience Releases Second Episode of Investor Video Series • ACCESS Newswire • 05/07/2026 01:25:00 PM
- Lexaria Updates Progress on Human Study #7 • ACCESS Newswire • 05/05/2026 01:10:00 PM
- Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications • ACCESS Newswire • 05/01/2026 01:25:00 PM
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended • ACCESS Newswire • 04/29/2026 01:10:00 PM
- Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs • ACCESS Newswire • 04/23/2026 01:05:00 PM
- Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales • ACCESS Newswire • 04/21/2026 01:10:00 PM
- Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property • ACCESS Newswire • 04/15/2026 01:10:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/13/2026 05:07:36 PM
- Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval • ACCESS Newswire • 04/07/2026 01:10:00 PM
- Lexaria to Begin New Human Clinical Study in GLP-1 • ACCESS Newswire • 04/01/2026 01:20:00 PM
- Lexaria's Robust Patent Portfolio Continues to Grow • ACCESS Newswire • 03/26/2026 01:20:00 PM
- Lexaria's Oral GLP-1 Drug Strategy Validated by Industry • ACCESS Newswire • 03/24/2026 01:15:00 PM
- Lexaria Announces New R&D Plans for 2026 • ACCESS Newswire • 03/04/2026 02:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 09:30:40 PM
- Lexaria Announces Positive Final Results From Human Pilot Study #5 • ACCESS Newswire • 02/05/2026 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/28/2026 06:51:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/28/2026 06:33:53 PM
- Lexaria Awarded Six Additional Patents • ACCESS Newswire • 01/22/2026 02:20:00 PM
- 5 Assets Securing the 2026 Biological Choke Point • GlobeNewswire Inc. • 01/21/2026 02:55:00 PM
- Lexaria Releases Annual Letter from the CEO • ACCESS Newswire • 01/12/2026 02:10:00 PM
- Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 • ACCESS Newswire • 12/30/2025 02:20:00 PM
- Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 • ACCESS Newswire • 12/23/2025 02:29:00 PM
- Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 12/16/2025 09:00:00 PM
- Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 12/15/2025 01:00:00 PM
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended • ACCESS Newswire • 11/12/2025 02:10:00 PM
